Sirio Pharma Enhances QA/QC with SirioSure; Targets Label Claim Compliance in US Market
Sirio Pharma, a leading CDMO, launched SirioSure, a comprehensive quality assurance initiative designed to guarantee label claim accuracy and product efficacy for brand owners. This program leverages pharmaceutical-grade QA/QC across the entire product lifecycle, from ingredient sourcing to final inspection.
City of Industry, United States — 16 January 2025
Sirio Pharma, a contract development and manufacturing organisation (CDMO), has introduced 'SirioSure', a comprehensive quality assurance and control (QA/QC) initiative for nutrition products. This programme is designed to provide brand owners with heightened confidence in label claim accuracy, ingredient levels, and overall product quality, drawing on Sirio's pharmaceutical manufacturing heritage. SirioSure encompasses extensive QA/QC protocols from ingredient vetting and formulation development to mass manufacture, final inspection, and commercialisation, aiming to assure long-term product efficacy.
The initiative integrates rigorous supplier vetting, detailed ingredient shelf-life analysis, and production line data collection, combined with advanced inspection technologies and unit-level traceability. This approach directly addresses industry concerns regarding product integrity, especially in light of a recent JAMA Network Open study. That study indicated that only 11% of nearly 60 tested supplements contained the advertised amounts of key ingredients, sparking negative press and eroding consumer trust.
SirioSure represents a proactive response to this market challenge, combining experienced quality management personnel with advanced laboratory equipment. The programme includes continuous process reviews and systemic digitisation to establish robust quality guardrails. Sirio Pharma's recent commitment to procure a gas chromatography-mass spectrometry (GC-MS/MS) system further underscores its investment in quality, enhancing capabilities for foreign particle and pesticide residue detection—a persistent industry-wide concern.
What this means for United States
US brand owners utilising CDMOs will find SirioSure’s enhanced QA/QC critical for mitigating regulatory risks from the FDA, which is increasing focus on label accuracy. This initiative directly supports compliance with Good Manufacturing Practices (GMPs) and strengthens brand reputation in a competitive market where consumer trust is paramount. Choosing a CDMO with pharmaceutical-grade QA/QC can provide a competitive edge, justifying premium pricing and supporting expanded distribution channels. It also reduces reformulation windows by ensuring initial product integrity, protecting margins. Brand owners should audit CDMOs for similar commitments to advanced testing protocols and comprehensive traceability systems, aligning with stricter industry demands and consumer expectations.
Sirio Pharma's General Manager for Europe & Americas, Sara Lesina, emphasised that the company's pharmaceutical background underpins its rigorous approach, ensuring products meet label claims and performance expectations. Ryan Li, Head of Quality, highlighted the leveraging of technological advancements, including AI and automated inspection systems, to continuously elevate quality standards and ensure food safety.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.